Nifty
Goldman Sachs Sees Strong Scope for Foreign Investors to Return to India

Lumic
about 2 months ago
Goldman Sachs Sees Strong Scope for Foreign Investors to Return to India
KEY POINTS
Goldman Sachs expects reversals with foreign fund inflows reducing on the current pessimism
The brokerage projects Nifty to reach 26,500 by June 2027, supported by a stronger domestic recovery
FIIs have already turned modest buyers since mid-June, with financial stocks attracting most inflows
LUMIC INSIGHT
Close to 10-12% rise in Nifty expected by 2027
This 'Insights' piece delves into Goldman Sachs' optimistic outlook on India's financial markets, suggesting a robust potential for foreign institutional investors (FIIs) to re-enter. The report highlights a projected 10-12% rise in the Nifty index by 2027, anticipating it to reach 26,500. This forecast is underpinned by an expected stronger domestic economic recovery. Notably, FIIs have already shown signs of renewed interest, turning into modest buyers since mid-June, with a particular focus on financial stocks. Goldman Sachs foresees a reversal of the current pessimism, paving the way for significant foreign fund inflows back into India's stock market.
More in Nifty

Lumic
3 days ago
Nifty
Closing Auction Session Cuts Derivatives Volume, Raising Liquidity concern
- August derivatives turnover hit multi-month lows on NSE and BSE after CAS changed trading
- NSE's August derivatives turnover fell to ₹34.48 lakh crore, lowest since November 2023
- Traders are closing positions earlier, reducing arbitrage and hedging activity near close
LUMIC INSIGHT
CAS volatility a big challenge for derivative traders
Economic Times·

Lumic
4 days ago
Nifty
Nifty Gainers & Losers 31st August: RBI Support Meets MSCI Rebalancing
- Pharma stocks led gains as a steadier rupee can help lower costs for imported inputs
- Sun Pharma gained 3.38%, leading Nifty as currency stability supported importers
- Adani stocks fell sharply as MSCI rebalancing flows drove heavy closing-auction moves
LUMIC INSIGHT
Rupee stability can benefit pharma by easing import costs
NSE·